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In the absence of effective endogenous repair mechanisms after cardiac injury, cell-based therapies have rapidly emerged as a potential novel
therapeutic approach in ischaemic heart disease. After the initial characterization of putative endothelial progenitor cells and their potential
to promote cardiac neovascularization and to attenuate ischaemic injury, a decade of intense research has examined several novel
approaches to promote cardiac repair in adult life. A variety of adult stem and progenitor cells from different sources have been examined
for their potential to promote cardiac repair and regeneration. Although early, small-scale clinical studies underscored the potential effects of
cell-based therapy largely by using bone marrow (BM)-derived cells, subsequent randomized-controlled trials have revealed mixed results
that might relate, at least in part, to differences in study design and techniques, e.g. differences in patient population, cell sources and prep-
aration, and endpoint selection. Recent meta-analyses have supported the notion that administration of BM-derived cells may improve
cardiac function on top of standard therapy. At this stage, further optimization of cell-based therapy is urgently needed, and finally,
large-scale clinical trials are required to eventually proof its clinical efficacy with respect to outcomes, i.e. morbidity and mortality.
Despite all promises, pending uncertainties and practical limitations attenuate the therapeutic use of stem/progenitor cells for ischaemic
heart disease. To advance the field forward, several important aspects need to be addressed in carefully designed studies: comparative
studies may allow to discriminate superior cell populations, timing, dosing, priming of cells, and delivery mode for different applications.
In order to predict benefit, influencing factors need to be identified with the aim to focus resources and efforts. Local retention and fate
of cells in the therapeutic target zone must be improved. Further understanding of regenerative mechanisms will enable optimization at
all levels. In this context, cell priming, bionanotechnology, and tissue engineering are emerging tools and may merge into a combined bio-
logical approach of ischaemic tissue repair.
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Background
Treatment of acute myocardial infarction (AMI) and ischaemic car-
diomyopathy includes rapid revascularization to limit ischaemic
damage and consecutive left ventricular (LV) dysfunction and
remodelling, and optimized secondary prevention strategies
aiming to attenuate progression of cardiac dysfunction and vascular
disease. As a result, the prevalence of heart failure from post-
ischaemic cardiac dysfunction rather increases1 causing a substan-
tial morbidity.2 Furthermore, despite modern medical therapy,
there is a substantial number of patients with ischaemic heart
disease refractory to current therapeutic approaches lacking
further treatment options, i.e. patients with angina pectoris and
no option of interventional or surgical revascularization.
After the initial description of putative endothelial progenitor cells
(EPCs) more than a decade ago,3 extensive research in the field of
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regenerative medicine has undermined the long-standing dogma that
some differentiated organs such as the heart cannot be repaired in
post natal life. We are standing on the merge to the era of biological
repair in ischaemic cardiovascular disease after the potential of
cardiac repair by a variety of stem and progenitor cell populations
has been revealed in pre-clinical and early clinical studies.
In the first part of this review, we recapitulate the status quo of
adult cell-based therapy in ischaemic heart disease with a clear
focus on randomized-controlled clinical trials where available. In
addition, we chose to include smaller-size, uncontrolled clinical
studies where randomized-controlled data are not available and
interesting insights are suggested. Due to space limitations, we
were unfortunately not able to include all clinical studies. In the
second part, we critically reflect limitations, uncertainties, and chal-
lenges of current approaches before finally discussing potential
roadmaps of future developments in the field of cell-based
cardiac repair. For a comprehensive review of stem and progenitor
cell biology, the reader is referred to other in-depth reviews.4– 8
Clinical experience from
cell-based therapy
By definition, stem cells are capable to self-renew and to generate
progenitor cells that continue to differentiate into lineage-
committed mature cells. Progenitor cells, hence, are more lineage-
determined, and therefore carry a more limited differentiation
potential and may proliferate for a finite number of divisions and
lack a self-renewal capacity. In this nomenclature, CD133 is a
marker of premature, rather undifferentiated, barely lineage-
committed stem and progenitor cells that is lost early during differ-
entiation, whereas expression of CD34 is maintained to later
stages.
The therapeutic use of unselected bone marrow cells that
contain stem and progenitor cells initially gained most momen-
tum and has been evaluated farthest in the clinic setting. More
recently, other adult stem and progenitor cells, such as circulating
stem and progenitor cells, resident cardiac stem cells, and
mesenchymal stem cells (MSCs) are being used in translational
studies for clinical applications (Figure 1). Skeletal myoblasts
(SMs) constitute another cell category that was considered suit-
able for cardiac repair. Each cell population seems to carry its
own profile of advantages, disadvantages, practical limitations,
and translational practicability.9
In the field of ischaemic heart disease, stem and progenitor cell-
based therapies have been applied after AMI, after remote
(chronic) myocardial infarction (CMI) with cardiac dysfunction
and/or in ischaemic cardiomyopathy, and for patients with intract-
able (chronic) angina pectoris that is not amenable to revasculari-
zation and is refractory to medical therapy. Dependent on the
targeted entity, different delivery routes have been used for cell
transfer.
Figure 1 Clinically examined as well as emerging stem and progenitor containing cell populations, and their delivery routes for the treatment
of ischaemic heart disease.
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Delivery routes for stem and progenitor
cell-based therapies
Conceptually, the goal is to safely deliver an optimal number of
effective cells as selective as possible to the therapeutic target
zone via a minimally invasive route. So far, cells have been trans-
planted into the heart overly via intracoronary infusion or intra-
myocardial injection (Figure 1).
Adapting the elegant, minimal-invasive technique lent from inter-
ventional cardiology for transvascular approaches, stem cells can
be homogenously distributed via intracoronary infusion. To
reduce spill-back and, in turn, optimize the contact time of cells
and coronary vessel wall, cells are infused in block-balloon tech-
nique.10 This approach is only feasible in patients with a patent
target vessel and, therefore, no option for non-revascularized
areas. In addition, its efficiency is impaired by a complex multistep
process of vessel adhesion and transmigration to allow infused
stem cells to invade the tissue. Then, homing of invaded cells is
also dependent on chemoattraction towards factors secreted
from the ischaemic tissue.11 In line with this concept, cardiac
homing of early EPCs after intracoronary infusion was increased
in patients with an acute compared with chronic MI.12 As a side
note, although intravenous infusion of stem/progenitor cells initially
appeared effective,13 low target zone cell concentration due to off-
target homing14 and biological redistribution15 strongly challenged
this transvascular strategy which cannot be favoured anymore.
The more invasive intramyocardial cell injection, on the other
hand, overcomes some of these hurdles and appears particularly
suitable in the case of non-revascularized infarct-related vessels
and/or ischaemic cardiomyopathy. Cells can be injected into the
myocardium from the epimyocardial side, commonly during open-
heart surgery, or endomyocardial side by means of needle-tipped
delivery catheters. Detouring the bloodstream has also been par-
ticularly attractive for large cell types such as MSCs and SMs. On
the downside, injection-related puncture of the viable or necrotic
myocardium comes with some risk, i.e. of ventricular perforation.
Further, injections lead to inhomogeneous distribution of cell clus-
ters in malperfused tissue. In this scenario, an elegant and now
commonly used catheter-based option is to guide the endomyo-
cardial injection by electromechanical mapping (EMM, e.g.
NOGA mapping). This technique enables to focus the cells to
ischaemic but viable (hibernating) myocardium.
For the future advance, however, it has to be kept in mind from
the clinician’s perspective that the more invasive the technique and
the higher percentage of co-morbidities introduced, the higher the
procedural risk in this group of commonly elderly, multimorbid
patients, who will be eligible for cell-based therapies.
Unselected bone marrow-derived cells
The use of unselected BM-derived mononuclearcells (BMCs) is clearly
the most examined cardiac cell-based therapy in clinical studies
(Figure 2) with a clinical follow-up experience up to 5 years.16 To
some extent, this development is the result of the pragmatic attractive-
ness of BMCs: (i) BMCs are rather easy to harvest, (ii) yielded cell
numbers do not limit clinical applications, (iii) while it remains
Figure 2 Selected completed and ongoing randomized-controlled clinical trials on cell-based therapy in ischaemic heart disease.
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unknown which cell types are more potent or have particular potent
repair properties, BMCscontain an ‘un-narrowed’ compositionof cells
including fractions of stem and progenitor cells, and (iv) their prep-
aration does not need prolonged ex vivo manipulation.
Acute myocardial infarction
After early-phase clinical studies had suggested the safety and feasi-
bility of intracoronary BMC infusion after AMI,10,17 –19 several mid-
sized, randomized, partly placebo-controlled trials have generated
mixed results. The randomized-controlled REPAIR-AMI and
BOOST trials showed an improvement of global LV ejection frac-
tion (LV-EF) without significant changes of LV end-diastolic
volumes 4–6 months after cell transfer.20,21 A REPAIR-AMI sub-
study revealed that the increase in LV-EF did not occur at the
expense of increases in end-systolic or end-diastolic volumes.22
Two other landmark studies, on the other hand, did not observe
a significant improvement in LV function or dimensions at 4- to
6-month follow-up,23,24 although Janssens et al.23 observed a
reduction in infarct size 4 months after intracoronary cell transfer
in a study with very early BMC administration (i.e. within 24 h).
Although definite reasons for these mixed results remain elusive,
differences in study protocol and design, including time from reper-
fusion to cell injection, type, number, and isolation technique of
cells, or follow-up design have been discussed. Whereas BMCs
were infused within the first 7 post-infarct days in most trials, in
Janssen’s trial, cells were injected within the 24 h after AMI.23 In
the ASTAMI trial, magnetic resonance imaging (MRI) was not per-
formed until 2–3 weeks after cell transfer, whereas only echocar-
diography was done at baseline. Further, cells by contrast were
prepared differently following the Lymphoprep technique.24 Sub-
sequently, follow-up data on the REPAIR-AMI and BOOST collec-
tives have become available. In REPAIR-AMI, the improvement of
LV function was sustained after 12 months20 and was associated
with a significant reduction in major adverse cardiovascular
events after AMI over this period;25 an observation that carried
on until 2 years of follow-up.26 Hence, in BOOST, the difference
in LV-EF between the groups was no longer significant after 18
months,27 although an echocardiographic substudy revealed a per-
sistent enhanced diastolic function from BMC application.28
Recently, 5-year follow-up data from the BOOST collective did
not show a sustained benefit on systolic and diastolic LV function
after a single BMC infusion.16 Interestingly, subgroup analyses
suggested that patients with a more severely impaired LV function
may have a benefit from BMC administration, whereas patients
with a rather preserved LV function post-MI may not benefit.
In the controlled but non-randomized BALANCE study,29 hae-
modynamics, measures of LV function and geometry, contractility,
infarct size, exercise capacity, and, of note, mortality remained
improved up to 5 years after BMC infusion when compared with
a matched, non-randomized control group. However, these
results should be interpreted with caution, given the non-
randomized design of the study. Another randomized study from
China with a long-term follow-up has recently suggested that
BMC administration may lead to an improved LVEF after 4
years.30 Notably, the results of the recently published REGENT
trial are discussed below, because one study arm received selected
CD34+/KDR+ BMCs.
Chronic myocardial infarction
In patients with CMI, less experience from clinical studies is avail-
able. The early-phase non-randomized IACT study by Strauer
et al.31 suggested that intracoronary BMC transfer more than 5
months after MI may result in smaller infarct size, better LV-EF,
and wall movement velocity associated with signs of higher
cardiac metabolism in the infarcted myocardium. This application
has been revisited by a carefully designed cross-over study
where intracoronary BMC transfer more than 3 months after MI
led to a significant improvement of LV-EF related to enhanced
regional contractility in the area of cell application.32 Of note,
this effect was also visible even in patients who crossed-over
from control or treatment with circulating progenitor cells.32
Strauer et al.33 have recently reported the long-term follow-up
data on the intracoronary application of BMCs in patients with
chronic heart failure (CHF) due to ischaemic cardiomyopathy
from the non-randomized STAR study. Over a 5-year follow-up,
intracoronary BMC administration was not associated with
adverse events. The authors reported an improved LV perform-
ance, quality of life, and survival in patients with CHF who
agreed to BMC application when compared with the control
group with a similar LV-EF, who did not agree to BMC treatment.33
However, due to the non-randomized design of the study, these
results need to be interpreted with caution.
Refractory myocardial ischaemia
Another set of early-phase studies has addressed the effect of BMCs
in patients with refractory myocardial ischaemia lacking options for
revascularization. These studies jointly suggest that BM-derived cell
injection via transepicardial (e.g. during bypass surgery) or transen-
docardial (e.g. guided via EEM) may improve subjective endpoints
such as angina frequency or heart failure symptoms, and/or
measures of global/regional wall motion and perfusion.34– 38 In the
randomized-controlled, double-blind trial conducted by van Ram-
shorst et al.,39 intramyocardial application of BMCs resulted in a
modest but significant improvement of myocardial perfusion as
assessed by SPECT, angina severity, and quality of life during a
3-month follow-up in patients with severe angina (classes III– IV),
despite optimal medical therapy, ineligible for myocardial revascu-
larization, and evidence of myocardial ischaemia at baseline. Simi-
larly, 6 months after direct injection of autologous BMCs in
patients with severe refractory angina, a significant improvement
of exercise time, LV function, and NYHA functional class was
observed in the PROTECT-CAD trial.40 The data of the
ACT34-CMI trial in a similar patient population are discussed below.
Cumulatively, the studies discussed above suggest feasibility and
some studies suggest efficacy of BMC-based therapy in acute/
chronic MI as well as chronic refractory angina. Recent
meta-analyses that summarized more than 1000 patients showed
a significant improvement in LV-EF after BMC therapy on top off
standard treatment.41–43 It needs to be acknowledged, however,
that LV-EF might not have been the ideal endpoint to clearly
detect efficacy (also see Endpoint selection). Overseeing safety
data from up to 5 years, no sustained safety issues associated
with the use of unselected BMCs have been observed after
cardiac transplantation in clinical studies.
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Circulating/mobilized CD1331 and
CD341 stem and progenitor cells
CD133 and CD34 are the most commonly used single markers
for the enrichment of haematopoietic stem cells (HSCs). The
observation that selection of certain cell populations, i.e.
CD34+ cells from total mononuclear circulating cells, may
augment their potency for cardiac repair has raised the interest
in using selected cell populations as opposed to unselected
BMCs.44 Baseline levels of circulating stem/progenitor cells are
known to be low, which restricts their therapeutic use. To lever-
age their therapeutic potential, these cell types can be pharma-
ceutically mobilized from the BM into the circulation in order
to be isolated and enriched (i.e. leukapheresis). Driven by the
history of the field, EPCs, a potential progeny of HSCs, have
been in the focus (for review see45,46).
CD1331 cells
CD133+ cells are more immature and less lineage-determined
than CD34+ cells. Intracoronary infusion of selected CD133+
cells after recent AMI has been evaluated in a small-scale, non-
randomized clinical study that revealed improved LV-EF paralleled
by a reduction in myocardial perfusion defect after 4 months.47
However, more coronary events, such as stent occlusion and
in-stent restenosis, were observed after CD133+ cell transfer.
The authors further reported a time-dependent adverse remodel-
ling of the infarct-related artery with accelerated luminal loss and a
reduced conductance after CD133+ cell transfer.48 However,
when CD133+ cells were injected locally during bypass surgery
in patients with recent AMI, no safety concerns became evident
in a small, non-randomized study, whereas regional wall motion
was improved associated with better myocardial perfusion and via-
bility.49 Transepicardial injection of CD133+ cells into the border
zone of MI during operative revascularization in patients who had
previous MI was reported by Stamm et al.50,51 in a small, uncon-
trolled study. Since no adverse events were reported, treatment
was considered safe and feasible. The conclusion that this treat-
ment resulted in improved LV function, however, is limited by
the lack of a control group.50,51
CD341 cells
CD34+ cells contain more endothelial lineage-determined cells
than CD133+ cells and are therefore considered as a cell popu-
lation enriched for ‘early‘ EPCs. In the randomized-controlled
REGENT trial, unselected and CD34+/CXCR4+-selected BMCs
were examined for their effects in LV function after MI in patients
with reduced LV function (EF 40%).52 After 6 months, LV-EF
increased by 3% in patients treated with unselected BMCs, 3% in
patients receiving CD34+/CXCR4+-selected BMCs, and remained
unchanged in the control group. There were, however, no signifi-
cant differences in absolute changes of LV-EF between the
groups.52 There was a trend in favour of BMC efficacy in individuals
with most severely impaired LV dysfunction, as has been observed
in several other studies using BMCs after acute MI.53 A potential
limitation of this trial was that MRI measurements of LV function
were only completed in a subgroup of patients.
We and others have evaluated intramyocardial injection of
CD34+ progenitors in coronary artery disease (CAD) patients
with chronic angina. Our Phase I/IIa pilot study suggested safety
and feasibility as well as a positive trend of bioactivity as evidenced
by SPECT perfusion imaging 6 months after CD34+ progenitor
cells were injected into the hibernating myocardium in patients
with refractory chronic angina; transendocardial delivery was
guided by EMM (NOGA mapping) to identify ischaemic but still
viable myocardium.54 These trends were further substantiated by
our subsequent Phase IIb randomized-controlled, multicentre
ACT34-CMI trial.55 In ongoing studies, this concept is under evalu-
ation for patients critical limb ischaemia (clinicaltrials.gov:
NCT00616980). So far, no safety issues are evident with the use
of CD34+ cells. Whether further selection using the combination
of different markers augments cellular repair capacity has to be
determined in the future.
Mesenchymal stem cells
Mesenchymal stem cells or stromal cells constitute another poten-
tial option for stem/progenitor cell-based therapy, and their use is
also evaluated as a potential allogeneic approach based on their
immunomodulatory properties. Mesenchymal stem cells are
stromal cells present in various tissues, such as BM and adipose
tissue. Reflecting their paracrine activity, they exert anti-
inflammatory and anti-apoptotic effects.56 Local immunosuppres-
sive action has fuelled hope of an allogeneic MSC transplantation
as an ‘of-the-shelf’ cell-based therapy to surround practical limit-
ations of cell resources and ex vivo culture often required in the
autologous setting.
The regenerative capacity of MSCs in general and the contro-
versially discussed aspect of immune privilege57,58 of allogeneic
MSCs needs to be evaluated in men. Autologous and allogeneic
MSC transfer is currently under investigation; however, clinical
data are scarce. In a randomized-controlled, double-blinded
Phase I study, intravenous application of allogeneic MSCs after
acute MI did not raise safety concerns and as assessed by a
global symptom score might be efficacious over a period of 6
months.59 In early studies, MSCs were injected intravenously;
however, the pulmonary passage of these large cells may be
problematic.60 Since these positive efficacy data stand in con-
trast to negative experience from intravenous BMC applications,
this set of data should still be considered with caution. Sub-
sequently, intracoronary application of MSCs after AMI has
been evaluated in two non-randomized early-phase studies by
Chen et al. A high-dose of BM-derived MSCs (6 × 1010)
resulted in a significant improvement of LV-EF in several modal-
ities,61 whereas a lower dose (5 × 106) did not improve LV
function in chronic ischaemic cardiomyopathy in a subsequent
study by the same authors.62 Still, MSC treatment resulted in
an improved exercise capability and heart failure symptomatol-
ogy after 3 months.
Adipose tissue can also serve as a source of MSCs, i.e. adipose
tissue-derived stem cells (ADSCs). Two clinical trials—APOLLO
and PRECISE—are exploring the safety, feasibility, and efficacy of
freshly isolated ADSCs with the CellutionTM system (Cytori Thera-
peutic Inc.) in patients with either AMI or CMI.
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Cardiac-derived cardiovascular stem
and progenitor cells
Until recently, our dogma was that the fully differentiated heart has
no capability for cell turnover and self-repair. In their elegant
observation, Bergmann et al.63 showed evidence for in-men cardi-
omyocyte renewal at a rate of 1% per year in younger adults and
0.5% in the elderly. In post-natal hearts, various subtypes of
tissue-resident cardiac stem and progenitor cells (CSCs) classified
by surface antigens and transcription markers have been reported,
although it is undetermined whether these subtypes have clearly
distinct phenotypes. Cardiac stem and progenitor cells, which
have been suggested to be capable of creating cardiomyocytes
and all surrounding cell types, are a promising candidate-at least
in theory-to provide contractility and vascularization.64 In the
light of the fact that their genuine number is low, CSCs isolated
from endomyocardial biopsies have successfully been expanded
ex vivo to leverage this therapeutic concept.65 Dr Marban’s group
has proposed a population of potential clinical relevance that has
been identified by expanding CSCs from self-adherent clusters
(cardiospheres) under certain conditions, i.e. cardiosphere-derived
stem cells (CDCs).66,67 There is still some controversy on the car-
diomyogenic potential of cardiospheres.68,69 Dr Field’s group has
recently suggested by using genetic cell tracking that there are tem-
poral limitations for the ability of cardiac-resident c-kit+ cells to
acquire a cardiomyogenic phenotype, i.e. that the cardiomyogenic
population is present in neonatal hearts but largely lost in adult
mouse hearts and suggested that elucidation of the underlying mol-
ecular mechanisms may permit a more robust cardiomyogenic
induction in adult-derived cardiac c-kit+ cells.70
Early-stage clinical studies currently address safety and feasibility
of cardiosphere-derived stem and progenitor cell transplantation.
In the SCIPIO trial (clinicaltrials.gov: NCT00474461), patients
with ischaemic cardiomyopathy from CMI who undergo bypass
surgery received an intracoronary infusion of autologous CSCs iso-
lated from their right atrial appendages. Further, patients with
ischaemic LV dysfunction from recent MI receive an intracoronary
injection of CDCs in the ongoing Phase I randomized
dose-escalation CADUCEUS trial (clinicaltrials.gov: NCT0089336).
Skeletal myoblasts
The concept of resident stem cells (i.e. satellite cells), which are
quiescent under normal conditions, contribute to new myocytes
in response to injury is rather well established for skeletal muscu-
lature. Skeletal myoblasts can be conveniently isolated from muscle
biopsies and ex vivo expanded for therapeutic use. After pre-clinical
evidence showed their repair effects in ischaemic myocardium,71,72
SMs have been thought to transdifferentiate into cardiomyocytes.
In the meanwhile, pre-clinical data indicate that SMs maintain a
skeletal muscle fate,73 infrequently fuse with cardiomyocytes,74
and hardly couple electromechanically with the host
myocardium.75
The clinical value of SMs is uncertain. Initially, several uncon-
trolled early-phase studies generated promising results for the
therapeutic utility of SMs in CHF, suggesting an improved
global and regional contractility and/or viability in the infarct
zone. In most studies, SMs were overly injected via a
transepicardial route during graft surgery,76–78 whereas only
one study reported the transendocardial injection of myoblasts
as safe and feasible.79 The most comprehensive clinical evalu-
ation of SMs, so far, has been the multicentre, randomized-
controlled, double-blind Phase II MAGIC trial.80 Herein, autolo-
gous, for 3 weeks ex vivo expanded SMs were directly adminis-
tered around the scar tissue in patients with ischaemic
cardiomyopathy who underwent bypass surgery. After 6
months, primary endpoints, namely global and regional LV func-
tion assessed by echocardiography, were not significantly
changed. Notably, the authors reported a significant reduction
in LV volumes in the high-dose group. The longest clinical
experience with SM transfer, however, has been published by
Dib et al. In their non-randomized, uncontrolled Phase I study,
patients undergoing surgery for revascularization or implantable
cardioverter-defibrillator implantation showed an increase in
LV-EF and viability, whereas no adverse events were observed
up to 4 years transepicardial injection of autologous SMs.81
Fuelled by an earlier report from Menasche et al.76 where
the use of myoblasts was associated with arrhythmic events
in 40% of the patients, SMs have been considered to be pro-
arrhythmogenic. In the subsequent MAGIC trial, no significant
increase in arrhythmic events was reported, although it must be
acknowledged that there was a trend towards more arrhythmias
in SM-treated patients despite treatment with amiodarone a
priori.80 Hence, none of the other early phase above nor the
4-year surveillance by Dib et al.81 has added evidence for
SM-induced sudden death. Chachques et al. hypothesized that
the arrhythmicity of SMs may be conditioned by the bovine
serum used during ex vivo expansion for 3 weeks (cellular cardio-
myoplasty) that may constitute an antigenic and thereby inflamma-
tory substrate. A strictly autologous preparation using the
corresponding donor serum in this rather small-sampled study
did not lead to any arrhythmias over 1–2 years of follow-up.82
As the majority of the above-mentioned, early-phase studies did
not report arrhythmic events, it remains vague whether this par-
ticular procedure stabilizes SMs electrically. There is still debate
about the potential pro-arrhythmicity of different adult stem/pro-
genitor cells, in particular the SMs.83,84 Further, in contrast to
earlier hesitations to infuse SMs intracoronary in the light of a
potential risk for microembolization due to their cell size, there
were no adverse events following transcoronary-venous SMs deliv-
ery observed in the POZNAN trial.85 The potential risk of arrhyth-
mias and sudden death needs, however, ultimate clarification for
this cell type.
Endogenous mobilization of stem/
progenitor cells
In contrast to exogenous cell transfer requiring invasive delivery,
adult stem/progenitor cells can be mobilized from the BM by sys-
temic administration of certain cytokines [e.g. granulocyte
colony-stimulating factor (G-CSF)] to augment circulating levels
of these cells and, thereby, enhance ischaemic tissue repair via cir-
culating stem/progenitor cells. This concept has been transferred
from the haematologists who isolate HSCs from the bloodstream
before ablation of the BM in stem cell transplantation.
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Earlier, the authors of the much debated MAGIC trial reported
that G-CSF mobilization after MI was associated with an unex-
pected higher rate of in-stent restenosis at the culprit lesion,
whereas intracoronary infusion of peripheral blood stem cells
appeared safe and potentially efficacious; because of this safety
issue, the study was discontinued.86 Subsequently, in a controlled,
non-randomized study by Ince et al.,87 G-CSF mobilization of
CD34+ BMCs shortly after angioplasty in AMI improved LV func-
tion and metabolic activity and attenuated LV remodelling up to 12
months without accentuation of the restenosis rate or late adverse
events. In the same line, Valgimigli et al.88 showed an unremarkable
safety profile for G-CSF in patients with AMI, although LV per-
fusion or function was unchanged 6 months after treatment. Fur-
thermore, G-CSF did not improve LV wall motion or perfusion
over the period of 1 month in patients with stable CAD.89 Of
note, there was a trend towards more ischaemia, and in 2 out of
16 patients reinfarction occurred.89 Early clinical experience with
stem cell mobilization by G-CSF from 10 trials, including 445
patients with AMI, was recently summarized in a meta-analysis
by Zohlnho¨fer et al. Herein, the authors concluded that cumulat-
ively the data do not support efficacy of endogenous stem cell
mobilization by G-CSF.90 Without evidence for efficacy on the
one side, and a potentially questionable safety profile on the
other (i.e. with respect to restenosis), large-scale trials, which
would be needed to clarify the clinical potential, could not be
advocated. Interestingly, very early G-CSF administration (,12 h)
has recently been reported to attenuate ventricular remodelling
after large, anterior MI, whereas systolic function and myocardial
perfusion were unchanged in the STEM-AMI collective.91
In recent years, pharmaceutical compounds emerged to modu-
late well-defined cascades of stem/progenitor cell biology and
homing. Continuing the concept of endogenous stem cell mobiliz-
ation, Zaruba et al.92 proposed a combined strategy of G-CSF
with dipeptidylpeptidase IV (DPP-IV) inhibition to improve cardiac
homing of mobilized stem/progenitor cells, which is currently
under clinical investigation in the SITAGRAMI trial in patients after
AMI. This concept proposes that inhibition of DPP-IV that is cleaving
one of the main stem cell attracting chemokines, SDF-1a, will
improve homing of mobilized stem/progenitor cells. More recent
results from our group and others described the CXCL12/
CXCR4 axis, the SDF-1a pathway, as a relevant regulator of
endogenous cell mobilization.93 In pre-clinical studies, the
CXCR4-antagonists Plerixafor (known as Mobozil or AMD3100)
mobilizes stem/progenitor cells from the BM, increases BM-derived
cell incorporation in the ischaemic border zone, and improves
cardiac function post-MI.93 Because this agonist has clinically been
used as HIV therapeutic without relevant side effects for years, its
safety profile appears favourable. To our knowledge, no clinical
data are available on any of these pharmaceutical strategies to thera-
peutically modulate endogenous stem/progenitor cell trafficking.
Emerging stem cell types with a potential
for cardiomyogenic differentiation
Embryonic stem cells
Embryonic stem cells (ESCs) posses several features that are con-
ceptually attractive for cardiac repair. Embryonic stem cells are
pluripotent, which means that they have the ability to differentiate
into all cell lineages.94,95 On the other hand, there are substantial
ethical and regulatory concerns with their retrieval. The limited
availability further hinders its therapeutic utility. In addition, there
is a risk for malignancies (i.e. intra- and extracardiac teratoma or
other tumour formation) associated with the use of ESCs,96,97 as
it has recently become evident in a patient who developed a
likely donor-derived multifocal brain tumour after treatment with
foetal neural stem cells.97 At the same time, reliable modalities
to regulate and control differentiation in a targeted and controlla-
ble fashion are challenging, although several approaches to limit
tumour formation have been explored, including strategies to
enhance cardiopoietic programming of ESCs.98
Furthermore, following allogeneic application, ESCs may trigger
an immune response in the recipient. Finally, it remains elusive
whether human ESCs efficiently structurally engraft and electrome-
chanically integrate into ischaemic myocardium. The above-
described limitations are some of the hurdles that currently
hinder the transition of ESC-based therapy into clinical translation.
Inducible pluripotent cells
In 2006, Takahashi and Yamanaka99 reported that differentiated
murine fibroblasts could be reprogrammed into stem cells with
the capacity to form all three germ layers and termed these cells
induced pluripotent stem cells (iPS). Nuclear reprogramming
with ectopic stemness factors has opened the opportunity to gen-
erate autologous patient-derived iPS from adult somatic cells.99,100
The ability of both mouse and human iPS to differentiate in func-
tional cardiomyocytes has recently been demonstrated.101,102
The study of iPS from selected cohorts of patients is an innova-
tive way to uncover molecular mechanisms of disease, such as
nicely illustrated in the study of Moretti et al.,103 who generated
pluripotent stem cells from dermal fibroblasts of patients with
long-QT syndrome type-1 and subsequently induced their differen-
tiation into functional cardiac myocytes that recapitulated the elec-
trophysiological features of the disorder.104
Functionally, intramyocardially injected undifferentiated iPS, but
not parental fibroblasts, engrafted and improved contractile func-
tion of infarcted myocardium while attenuating adverse remodel-
ling in immunocompetent mice.105 Only in immunocompetent
mice, the environment after cardiac transplantation was permissive
for differentiation, whereas in immunodeficient mice, tumour
development was observed, which highlights the importance of
immune surveillance to prevent tumour growth.105 New technol-
ogies such as small molecule screen and epigenetic modifications
most probably will establish further potentially more safe options
for the generation of iPS. It will, however, be crucial to validate
the epigenetic and phenotypic stability in the reprogrammed
state. Also, reprogramming pluripotency in somatic cells comes
with the risk of tumorigenicity as described above. Furthermore,
iPS become immunologically relevant while they differentiate
with up-regulation of histocompatibility antigens. This aspect
would narrow the range of applications to the autologous
setting.106 As described above, several important hurdles have to
be resolved before a clinical translation of iPS-based therapies
can be considered, including safety issues to prevent tumour
growth that may require determination of the appropriate
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differentiation of iPS-derived cells and removal of residual undiffer-
entiated cells before transplantation.107 In addition, upscaling for an
effective iPS-based cell generation will be required. Several impor-
tant considerations in the proposed mechanisms of cell-based
therapy for cardiac repair and its further development are
described in the Supplementary material online and depicted in
Figures 3–5.
Future directions of cell-based
therapy: a roadmap
Various strategies have been proposed to support stem cells in the
hostile environment of ischaemic tissue characterized by ischaemia,
acidosis, inflammation, and oxidative stress. Beyond the modu-
lation of cell homing, viability, engraftment, and retention, it
becomes more and more clear that true repair of damaged myo-
cardium will need more than a single-dose administration of cells.
Priming of stem and progenitor cells to
enhance their therapeutic efficacy
The concept to pre-treat or modify stem/progenitor cells before
application (priming) and thereby enhance their therapeutic
potency has evolved from earlier pre-clinical observations.108 – 114
These strategies basically target any function step that influences
cell fate from the application on: adhesion/transmigration,
homing, migration, engraftment, survival, cell–cell interaction,
repair capacity, differentiation, and retention. Potential tools for
modification include drugs, small molecules, naked and vector-
facilitated plasmids, and epigenetic reprogramming (for more
details see115,116). Priming of dysfunctional autologous cells from
cardiovascular patients via any of these tools may allow for a ‘reset-
ting of impaired biopotency’.
Among multiple targets stemming from pre-clinical evaluation,
the following examples are under clinical investigation: we and
others have identified a reduced endothelial NO synthase-
dependent NO production as an important mechanism limiting
the functional repair capacity of endogenous progenitor cells in
patients with diabetes or hypertension.108,117 In the randomized,
placebo-controlled ENACT-AMI trial, the therapeutic use of
eNOS-overexpressing EPCs is presently studied in patients with
large MI (clinicaltrials.gov: NCT00936819).118 As another
example of modified stem/progenitor cells, in the MESAMI II trial
(clinicaltrials.gov: registration in process) designed by Roncalli
and colleagues, patients with no-option chronic ischaemic cardio-
myopathy will receive an intramyocardial injection of MSCs pre-
treated with melatonin. This concept is based on pre-clinical data
showing that pre-treatment with the pineal hormone increases
survival, paracrine activity, and therapeutic efficiency of MSCs in
a rodent ischaemia model.119 Another way to boost paracrine
and differential cell functions is to pre-stimulate cells before appli-
cation.120,121 This concept is currently translated into patients with
Figure 3 Proposed mechanisms of ischaemic tissue repair via stem and progenitor cell-based therapies.
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heart failure from ischaemic cardiomyopathy by pre-incubation of
BM-derived MSCs with growth factors to guide their transition into
cardiopoietic cells (C-Cure trial, clinicaltrials.gov: NCT00810238).
As no clinical study of primed stem cells has been completed
yet, it is going to be interesting whether these strategies will
hold promise in clinical applications. Many more targeted cell
modifications can be expected to be in transition from bench to
bedside at present.
Bionanotechnology to support cell-based
therapies
In addition to the harmful biochemical milieu, loss of tissue archi-
tecture and loss of matrix support within the infarcted myocar-
dium detrimentally affect cell–cell and cell–matrix interaction
and, in turn, regulation of dependent pathways that are functionally
inevitable for the homeostasis of transplanted cells. The rapidly
evolving field of bionanotechnology allows to specifically design
biomaterials to support transplanted cells within this ischaemic
environment.122 Herein, the structure, dimensions, and shape of
constructs are pivotal to better mimic the native architecture of
extracellular matrix. An optimal biomaterial to support cell
therapy should provide a three-dimensional environment to
enhance biomechanical properties of extracellular matrix; a
purpose for which controlled organization at nano-scale is
needed (for more details see123). In some biomatrices, bioactive
signals can be incorporated to specifically modulate stem cell
biology while supporting them structurally.124
The strategy to support cell transfer has rapidly gained attention
triggered by exciting pre-clinical data. In murine models, nanofibres
that self-assemble into a matrix recruited endogenous progenitors
to the myocardium and supported transplantation of cardiomyo-
cytes providing a microenvironment.125 In principle, biomaterials
can be custom-designed to optimally fit the organ-specific micro-
environment.126 Furthermore, bioactive signals can be incorpor-
ated in some biomaterials to additionally enhance cell survival,
retention, proliferation, and differentiation. In this context,
Padin-Iruegas et al.127 reported that an insulin-like growth factor
carrying nanofibre enhances CSC-dependent repair of cardiac
injury.128 In our hands, the combination of a linage-specific opti-
mized, self-assembling nanofibre enhances the potency of
cell-therapy in ischaemic tissue repair.129 Also, bioactive sequences
of biologically attractive paracrine factors, e.g. SDF-1, can more
effectively be presented via biomaterials with the aim to recruit
endogenous into or support exogenously applied cells in ischaemic
myocardium.130
Although emerging results for the role of bionanomaterials in
cell-based ischaemic tissue repair are promising, there has not
been precedence in humans. Before any clinical translation,
several aspects such as dosing, dynamics and kinetics of bioactivity,
biodegradability, occurrence and excretion of breakdown pro-
ducts, and immune compatibility have to be carefully addressed.
Tissue engineering
Tissue engineering has now been advanced for several years. In
particular aiming at replacement of the myocardium, the break-
through in this field has been hindered by several challenges.
While cell seeding of construct backbones has worked well for
proliferative and hypoxia-tolerant cells, it has been difficult to
achieve tissue-like densities with cells with low proliferation rate
such as cardiomyocytes,122 although successful generation and
transplantation of engineered heart tissue grafts has been reported
in small animal models.131 Achieving sufficient perfusion of larger
constructs is challenging. Passive diffusion is generally tolerated
up to a distance of ,0.1–0.2 mm. In the case of longer distances,
dysfunctionality and necrosis occur as a failure of sufficient diffu-
sion.132 At present, bigger, more complex constructs such as myo-
cardium (1.0–1.5 cm) cannot be maintained by simple diffusion
and need anastomosis to a vascular network. Since generation of
a stable and functional construct microenvironment remains criti-
cal, stem and progenitor cells display a strong potential to acceler-
ate tissue engineering for the purpose of seeding but also for the
creation of a vascular networks.133
Figure 4 Open questions for the optimization of the therapeutic efficacy of stem and progenitor cells.
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Combined strategies of biological repair
As stated above, single-dose transfer of a single cell type into a
deranged environment will likely not be sufficient to ‘regenerate’
a complex tissue such as the heart. More recent insights suggest
that combined strategies of biological repair more closely resemble
native biological mechanisms and, thus, may be more potent than
current one-stop, single-cell strategies (Figure 5). Conceptually, the
combination of different types of stem/progenitor cells with
stromal cells is functionally very attractive aiming at synergisms.
Different cell (sub-) populations may exert different regenerative
effects. Unselected and selected cells, for example, showed differ-
ent spatial patterns of homing.15 Melero-Martin et al.133 recently
described striking evidence for the synergistic interaction of
EPCs and MSCs, which contain relevant pericytes, to create a sub-
stantial and functional vascular network in a Matrigel assay that was
stable for up to 4 weeks.
To add yet another level of complexity, supplemental tools that
are aimed to improve efficacy of cell transfer have become available.
Engraftment of cardiac-derived stem cells (CSCs) after intramyocar-
dial application, for example, is improved after sealing the injection
site with fibrin glue to attenuate the known leakage of cell suspen-
sion.134 Low-energy shock wave treatment of the target tissue has
been shown to enhance recruitment of circulating EPCs by enhan-
cing local expression of chemoattracting growth factors in
mice.135 This technology is thought to prepare the ischaemic
target zone for cell transfer and thereby indirectly augment cell
homing and retention. In the ongoing Cellwave study (clinicaltrials.-
gov: NCT00326989), extracorporal shock wave pre-treatment
before intracoronary application of BM-derived progenitor cells is
already under clinical evaluation in patients with CMI. In addition,
homing of cells via the intracoronary route can be improved by dis-
rupting cell-carrying microbubbles via ultrasound. Without evoking
undesired damage, this technology appears to facilitate vascular
transmigration by creating capillary pores.136,137
With all limitations and shortcomings in mind, the idea to realize
effective cardiac tissue repair by using only one cell type is likely
challenging. Depending on further mechanistic and clinical insights,
we envision combined, precisely timed, multi-step approaches that
incorporate various stem and stromal cells, paracrine factors, and
specifically bioengineered tools for the future cardiac regenerative
medicine in order to advance this exciting field to the next level,
the level of true ischaemic tissue repair.
Summary
We are currently in the phase of translation of cardiac cell-based
therapy, and good translation without any surprise takes time
and efforts. After the initial hype revolving cell-based cardiac
tissue repair led to a rather rapid translation into early-phase clini-
cal trials, we have now reached the stage where conclusive
answers and thoughtful fine-tuning, which includes a step back to
the bench to find answers, are needed. There is some consensus
that cell-based therapy has potential beneficial effects on top of
standard medial therapy as it has been expressed by the task
force of European Society of Cardiology.138 Apart from uncertain-
ties and limitations discussed above, several pressing tasks need to
be addressed: sustained efficacy needs to be proven for each cell
type depending on the treated entity. Comparative studies may
allow discriminating superior cell populations, sources, timing,
dosing, and delivery mode considering with regard to certain appli-
cations. Safety profiles dependent on cell type, delivery route, and
underlying disease need to be characterized by long-term
follow-up of larger collectives. To substantiate these aspects,
large-scale, multicentre trials are clearly needed. In order to
predict benefit, influencing factors need to be identified with the
aim to focus resources and efforts. Local retention and fate of
cells in the therapeutic target zone must be improved. Further
understanding of regenerative mechanisms will enable optimization
at all levels. Cell priming, bionanotechnology, and tissue engineer-
ing are emerging tools and may merge into a combined biological
approach of ischaemic tissue repair.
After a hectic decade, it is time to catch breath and focus efforts
on concise pre-clinical work, and thoughtfully designed, sufficiently
powered clinical trials to find answers to important remaining
questions, to clarify on uncertainties, and to overcome limitations
with the aim to optimize cell-based therapy. Despite all promise,
eventually, we are challenged to show robust effects on disease
progression, morbidity, and mortality associated with an accepta-
ble safety profile to advance the promising concept of cell-based
therapy to clinical routine.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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